These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 35273398)

  • 1. Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer.
    Toshimitsu K; Takano A; Fujii M; Togasaki K; Matano M; Takahashi S; Kanai T; Sato T
    Nat Chem Biol; 2022 Jun; 18(6):605-614. PubMed ID: 35273398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
    Xie BY; Wu AW
    Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids.
    Mao Y; Wang W; Yang J; Zhou X; Lu Y; Gao J; Wang X; Wen L; Fu W; Tang F
    Protein Cell; 2024 Apr; 15(4):285-304. PubMed ID: 37345888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
    Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
    Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer.
    Cho YW; Min DW; Kim HP; An Y; Kim S; Youk J; Chun J; Im JP; Song SH; Ju YS; Han SW; Park KJ; Kim TY
    Mol Oncol; 2022 Jun; 16(12):2396-2412. PubMed ID: 34850547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective derivation of a living organoid biobank of colorectal cancer patients.
    van de Wetering M; Francies HE; Francis JM; Bounova G; Iorio F; Pronk A; van Houdt W; van Gorp J; Taylor-Weiner A; Kester L; McLaren-Douglas A; Blokker J; Jaksani S; Bartfeld S; Volckman R; van Sluis P; Li VS; Seepo S; Sekhar Pedamallu C; Cibulskis K; Carter SL; McKenna A; Lawrence MS; Lichtenstein L; Stewart C; Koster J; Versteeg R; van Oudenaarden A; Saez-Rodriguez J; Vries RG; Getz G; Wessels L; Stratton MR; McDermott U; Meyerson M; Garnett MJ; Clevers H
    Cell; 2015 May; 161(4):933-45. PubMed ID: 25957691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
    Ren X; Chen W; Yang Q; Li X; Xu L
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug screening by uniform patient derived colorectal cancer hydro-organoids.
    Jung YH; Choi DH; Park K; Lee SB; Kim J; Kim H; Jeong HW; Yang JH; Kim JA; Chung S; Min BS
    Biomaterials; 2021 Sep; 276():121004. PubMed ID: 34273688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling colorectal cancers using multidimensional organoids.
    Sayed IM; El-Hafeez AAA; Maity PP; Das S; Ghosh P
    Adv Cancer Res; 2021; 151():345-383. PubMed ID: 34148617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes.
    Takeda H; Kataoka S; Nakayama M; Ali MAE; Oshima H; Yamamoto D; Park JW; Takegami Y; An T; Jenkins NA; Copeland NG; Oshima M
    Proc Natl Acad Sci U S A; 2019 Jul; 116(31):15635-15644. PubMed ID: 31300537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Derived Organoid Model in the Prediction of Chemotherapeutic Drug Response in Colorectal Cancer.
    Hao M; Cao Z; Wang Z; Xin J; Kong B; Xu J; Zhang L; Chen P
    ACS Biomater Sci Eng; 2022 Aug; 8(8):3515-3525. PubMed ID: 35696669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
    Narasimhan V; Wright JA; Churchill M; Wang T; Rosati R; Lannagan TRM; Vrbanac L; Richardson AB; Kobayashi H; Price T; Tye GXY; Marker J; Hewett PJ; Flood MP; Pereira S; Whitney GA; Michael M; Tie J; Mukherjee S; Grandori C; Heriot AG; Worthley DL; Ramsay RG; Woods SL
    Clin Cancer Res; 2020 Jul; 26(14):3662-3670. PubMed ID: 32376656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-content, targeted RNA-seq screening in organoids for drug discovery in colorectal cancer.
    Norkin M; Ordóñez-Morán P; Huelsken J
    Cell Rep; 2021 Apr; 35(3):109026. PubMed ID: 33882314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology.
    Sasaki N; Clevers H
    Curr Opin Genet Dev; 2018 Oct; 52():117-122. PubMed ID: 30261425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.
    Weeber F; van de Wetering M; Hoogstraat M; Dijkstra KK; Krijgsman O; Kuilman T; Gadellaa-van Hooijdonk CG; van der Velden DL; Peeper DS; Cuppen EP; Vries RG; Clevers H; Voest EE
    Proc Natl Acad Sci U S A; 2015 Oct; 112(43):13308-11. PubMed ID: 26460009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organoid in colorectal cancer: progress and challenges.
    Ji DB; Wu AW
    Chin Med J (Engl); 2020 Aug; 133(16):1971-1977. PubMed ID: 32826461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Proteome Profiles of Healthy and Tumor Human Colon Organoids Reveal Both Individual Diversity and Basic Features of Colorectal Cancer.
    Cristobal A; van den Toorn HWP; van de Wetering M; Clevers H; Heck AJR; Mohammed S
    Cell Rep; 2017 Jan; 18(1):263-274. PubMed ID: 28052255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling colorectal cancer: A bio-resource of 50 patient-derived organoid lines.
    Engel RM; Jardé T; Oliva K; Kerr G; Chan WH; Hlavca S; Nickless D; Archer SK; Yap R; Ranchod P; Bell S; Niap A; Koulis C; Chong A; Wilkins S; Dale TC; Hollins AJ; McMurrick PJ; Abud HE
    J Gastroenterol Hepatol; 2022 May; 37(5):898-907. PubMed ID: 35244298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A growth factor-reduced culture system for colorectal cancer organoids.
    Tan R; Zhang Z; Ding P; Liu Y; Liu H; Lu M; Chen YG
    Cancer Lett; 2024 Apr; 588():216737. PubMed ID: 38382667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciphering the Tumor Microenvironment of Colorectal Cancer and Guiding Clinical Treatment With Patient-Derived Organoid Technology: Progress and Challenges.
    Li J; Liu J; Xia W; Yang H; Sha W; Chen H
    Technol Cancer Res Treat; 2024; 23():15330338231221856. PubMed ID: 38225190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.